Research brief: Antibody drug to protect pancreas in diabetics

A trial to test whether the monoclonal antibody rituximab can preserve pancreas function in type-1 diabetes is to begin in April, researchers from Indiana University in the US have announced. The researchers believe rituximab could also save pancreatic function in patients with type-1 diabetes because it attacks B lymphocytes thought to prime T cells to attack the pancreas.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus